Loading cancer entity…
Loading cancer entity…
Clinical trials
101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01701843 | Cromoglicate in Mastocytosis | terminated | Phase 2 | 7 | LEO PharmaINDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04846348 | Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis | terminated | Phase 2 | 1 | Joseph ButterfieldOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT03214666 |
| terminated |
| Phase 1 / Phase 2 |
| 12 |
| GT Biopharma, Inc.INDUSTRY |
| 1 |
| Nov 10, 2022 |
| clinicaltrials |
| NCT02415608 | Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis | terminated | Phase 2 | 4 | Jason Robert GotlibOTHER | 1 | Sep 20, 2018 | clinicaltrials |
| NCT00387426 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00918931 | Obatoclax for Systemic Mastocytosis | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 4, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Feb 24, 2025source: clinicaltrials